selected scholarly activity
-
chapters
-
conferences
- Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada. Acta Haematologica. 1-13. 2025
- COMPARISON OF NEXT GENERATION SEQUENCING VERSUS SINGLE ANALYTE TESTS FOR SOMATIC MUTATION DETECTION IN ACUTE MYELOID LEUKEMIA, MYELOPROLIFERATIVE NEOPLASM AND SOLID TUMORS. International Journal of Laboratory Hematology. 72-72. 2017
- Improved Survival from Transfusion Dependence in Lower-Risk MDS Receiving Iron Chelation, Adjusting for MDS and Patient Characteristics: An MDS-Can Analysis. Leukemia Research. S162-S163. 2017
- MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System. Leukemia Research. S131-S132. 2017
- Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood. 3192-3192. 2016
- Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood. 1922-1922. 2016
- A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes. Blood. 4446-4446. 2015
- Assessing Disease Stability of Patients with Myelodysplastic Syndrome for an Age of Blood Randomized Controlled Trial: A Chart Review. Blood. 5252-5252. 2015
- Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. Blood. 2015
- Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). Blood. 2015
- Multi-molecular complexes of Bcl-2 proteins regulate membrane permeabilization by Bax. Oncology Research and Treatment. 99-100. 2015
- ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). Haematologica. 61-62. 2015
- Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. Blood. 2014
- Conformation dictates function: Membrane associated interactions of Bcl-XL with Bax, c(t) Bid and Bad. Oncology Research and Treatment. 280-280. 2014
- EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR. Haematologica. 532-532. 2014
- Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. Journal of Clinical Oncology. 7025-7025. 2014
- A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood. 821-821. 2013
- Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. Blood. 94-95. 2013
- Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care. Blood. 3656-3656. 2013
- Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up. Journal of Clinical Oncology. 2013
- P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry. Leukemia Research. S76-S76. 2013
- Binding and Oligomerization of Bcl-2 Family Proteins on Supported Lipid Bilayers with Single Molecule Resolution. Biophysical Journal. 222a-222a. 2013
- Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up. Journal of Clinical Oncology. 2012
- A Supported Bilayer Model to Study the Effect of Membrane Composition on Bcl-2 Family Proteins. Biophysical Journal. 647a-647a. 2012
- Quantification of Protein Distribution on Liposomes using Confocal Microscopy: A Single Mobile Fluorescent Particle Detection Method. Biophysical Journal. 51a-52a. 2012
- tBid Conformational Changes at the Membrane for the Regulation of Apoptosis. Biophysical Journal. 625a-625a. 2012
- Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood. 278-278. 2011
- Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients. Blood. 194-195. 2011
- Evaluation of a novel class of sulfonanilides for targeted treatment of multiple myeloma: Dual-mechanism compounds inhibiting HIF1 alpha-signaling and inducing apoptosis. Onkologie: international journal for cancer research and treatment. 18-18. 2011
- Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth in vivo. Cancer Research. 660-660. 2011
- A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis. Blood. 1232-1232. 2010
- Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells. Blood. 1343-1344. 2010
- Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level.. Blood. 1624-1625. 2010
- 58 Development and characterization of novel orally available Hypoxiainducible factor (HIF) signaling inhibitors as dual-mechanism cancer therapeutics. European Journal of Cancer, Supplement. 27-27. 2010
- Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).. Journal of Clinical Oncology. 6564-6564. 2010
- Bax Pore Formation: From Activation to Oligomerization. Biophysical Journal. 464a-464a. 2010
- Effect of Different Lipid Compositions on Mitochondrial Outer Membrane Permeabilization Assisted by the Pro-Apoptotic Proteins tBID and BAX. Biophysical Journal. 465a-465a. 2010
- Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. Blood. 823-823. 2009
- Binding of the Pro-Apoptotic protein Bid to Mitochondrial Membranes is a Two Step Process. Biophysical Journal. 425a-425a. 2009
- A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood. 587-587. 2007
- A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over.. Blood. 899-899. 2007
- A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood. 908-908. 2007
- Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.. Blood. 1095-1095. 2007
- Characterizing Bax-tBid function at the mitochondrial membrane isolated from bak(-/-) mice. Biochemistry and Cell Biology. 1077-1078. 2006
- Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura: A case report. Transfusion. 44A-45A. 2006
- A phase II trial of oblimersen sodium (G3139) plus rituximab for treatment of patients with recurrent B-cell non-Hodgkin's lymphoma. Annals of Oncology. 68-68. 2005
- Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 587S-587S. 2005
- A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study.. Journal of Clinical Oncology. 585S-585S. 2004
- Final analysis of a randomized phase I study of the C-RAF kinase inhibitor BAY 43-9006 in patients with acute myeloid leukemia. Annals of Oncology. 154-154. 2004
- Investigation of the oligomerization of Bax at the membrane of a giant vesicle. Biophysical Journal. 462A-462A. 2004
- Ganciclovir prophylaxis is associated with delayed neutrophil engraftment in patients undergoing haploidentical transplantation.. Blood. 439B-439B. 2003
- Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells.. Blood. 439A-439A. 2003
- A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada clinical trials group study. Blood. 267B-267B. 2002
- Dynamic membrane topology of Bcl-2 during apoptosis.. The FASEB Journal. A522-A522. 2002
- Complete remission of acute promyelocytic leukemia with ATRA.. Blood. 222B-222B. 2001
- Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. Molecular Biology of the Cell. 25A-25A. 2001
- Mutants with restricted subcellular localization reveal different mechanisms and potencies for Bcl-2 and Bcl-XL mediated inhibition of doxorubicin induced apoptosis.. Clinical Cancer Research. 3719S-3720S. 2001
- Myc expression is essential for Bax conformational change and cytochrome c release in an organelle specific apoptotic pathway. The FASEB Journal. A169-A169. 2001
- Assessing pore formation by Bcl-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment.. Blood. 174B-174B. 2000
- Early loss of adhesion during apoptosis is independently regulated by BCL-2 and caspases.. Blood. 184B-184B. 1999
- Caspase dependent O-glycosylation of E-cadherin results in loss of cell adhesion during apoptosis.. Molecular Biology of the Cell. 187A-187A. 1999
- Bcl-2 prevents internalization of but not caspase dependent O-glycosylation of E-cadherin. The FASEB Journal. A1341-A1341. 1999
- CD34+ t(15;17) APL represents a distinct subgroup associated with CD2+, bcr3 isoform, microgranular morphology, a high white count and a poor prognosis.. Blood. 604A-604A. 1998
- Bcl-2 increases E-cadherin mediated cell adhesion prior to onset of apoptosis. Molecular Biology of the Cell. 244A-244A. 1998
- The entity of CD34+ t (15; 17) acute promyelocytic leukemia. British Journal of Haematology. 100-100. 1998
- BCL-2 and Bax regulate apoptosis from different subcellular compartments.. Blood. 3598-3598. 1997
- BCL-2 and bax regulate apoptosis from different subcellular compartments. Molecular Biology of the Cell. 2033-2033. 1997
- Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types.. Blood. 2199-2199. 1996
- Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types. The FASEB Journal. 519-519. 1996
- Radiation induced apoptosis in neuroblastoma does not depend on induction of Bax. Pediatric Research. 925-925. 1996
- Bax is induced following retinoic acid treatment but cell survival depends on Bcl-2 expression. Blood. 133-133. 1995
- The effect of targeting Bcl-2 to different intracellular compartments. Blood. 2920-2920. 1995
- The role of Bcl-2 expression in mediating cisplatinum resistance.. Blood. 3113-3113. 1995
- DAY-6 BONE-MARROW (D6BM) PREDICTS FOR COMPLETE REMISSION (CR) IN ADULTS WITH ACUTE MYELOID-LEUKEMIA (AML). Blood. A303-A303. 1994
- TELOMERE LENGTH AND TELOMERASE ACTIVITY IN HEMATOLOGIC MALIGNANCIES. Blood. A38-A38. 1994
- EVIDENCE FOR PROMISCUOUS MEMBRANE ASSEMBLY OF BCL-2. Blood. A114-A114. 1993
- SUBCELLULAR-LOCALIZATION OF BCL-2 - THE HYDROPHOBIC CARBOXYL TERMINAL DOMAIN TARGETS BCL-2 TO MEMBRANES. Journal of Cellular Biochemistry. 266-266. 1993
- GENE PROBE ANALYSIS OF HODGKINS AND NON-HODGKINS LYMPHOMAS. British Journal of Haematology. 142-142. 1988
- ANALYSIS OF T-CELL ASSOCIATED REARRANGEMENT OF THE T-CELL RECEPTOR GAMMA-CHAIN GENES IN B-CLL. British Journal of Haematology. 506-506. 1988
- GENOTYPES AND IMMUNOPHENOTYPES OF HODGKINS-DISEASE DERIVED CELL-LINES. Blut. 248-248. 1987
-
journal articles
- Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.. Cancer. 131:e35845. 2025
- A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.. Future Oncology. 21:929-941. 2025
- "Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype": comment from Al Sharif et al.. Journal of Thrombosis and Haemostasis. 23:1123-1126. 2025
- Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.. Current Oncology. 32:118. 2025
- Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.. Transplantation and Cellular Therapy. 31:77.e1-77.e20. 2025
- Improvement in quality of life in MDS patients who become transfusion independent after treatment.. Leukemia and Lymphoma. 66:279-288. 2025
- Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry.. Annals of Hematology. 103:5241-5248. 2024
- Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. The Lancet Oncology. 25:463-473. 2024
- Identification of cells of leukemic stem cell origin with non-canonical regenerative properties. Cell Reports Medicine. 5:101485-101485. 2024
-
Long‐term follow‐up of
VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. American Journal of Hematology. 99:615-624. 2024 - The successful management of acute promyelocytic leukemia during pregnancy: a case report. Leukemia and Lymphoma. 65:526-529. 2024
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 38:502-512. 2024
- Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies. American Journal of Hematology. 99:473-476. 2024
-
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial
RBC‐ENHANCE . Transfusion. 64:223-235. 2024 - Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. The Lancet Haematology. 11:e15-e26. 2024
-
Final report of
TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD ) study. British Journal of Haematology. 203:781-791. 2023 - Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia Research. 133:107374-107374. 2023
- Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Reports Medicine. 4:101108-101108. 2023
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58:478-490. 2023
- The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes. eLife. 12:e88329. 2023
- Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19:e559-e569. 2023
- The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia and Lymphoma. 64:651-661. 2023
- High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes. Haematologica. 108:532-542. 2023
-
Perioperative management of myeloproliferative neoplasms: A
pan‐Canadian physician survey and international expert opinion. American Journal of Hematology. 97:E466-E469. 2022 - Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy. Current Oncology. 29:6794-6806. 2022
- The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of Hematology. 101:1023-1030. 2022
- Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells. Science Advances. 8:eabm7375. 2022
- BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology. 196:136-145. 2022
- Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology. 100:1917-1918. 2021
- Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study. British Journal of Haematology. 194:319-324. 2021
- Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology. 100:1181-1194. 2021
- Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. British Journal of Haematology. 193:779-791. 2021
- Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Current Oncology. 28:1376-1387. 2021
- Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. Cell Reports. 34:108845-108845. 2021
- Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. Cell Reports Medicine. 2:100202-100202. 2021
- A BERT model generates diagnostically relevant semantic embeddings from pathology synopses with active learning. Communications Medicine. 1:11. 2021
- Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma. 61:3287-3305. 2020
- Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia. 34:3434-3438. 2020
- Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology. 13:92. 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine. 383:617-629. 2020
- Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncology Practice. 16:351-359. 2020
- An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia. 34:1394-1406. 2020
- Hand Mirror Cells and Hypercalcemia: A Rare Presentation of Pediatric Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 42:e181-e184. 2020
- Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax. Molecular Cell. 77:901-912.e9. 2020
- The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells. eLife. 9:e44525. 2020
- The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. Leukemia Research. 88:106285-106285. 2020
- Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leukemia and Lymphoma. 60:3493-3502. 2019
- Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. eLife. 8:e37689. 2019
- How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. European Journal of Haematology. 102:36-52. 2019
- Unleashing Blocked Apoptosis in Cancer Cells: New MCL1 Inhibitors Find Their Groove. Cancer Discovery. 8:1511-1514. 2018
- Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research. 74:21-41. 2018
- Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell. 34:483-498.e5. 2018
- Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Reports. 19:e45235. 2018
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances. 2:1935-1945. 2018
- Cyclic thrombocytopenia with statistically significant neutrophil oscillations. Clinical Case Reports. 6:1347-1352. 2018
- A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. Annals of Hematology. 96:2025-2029. 2017
- Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nature Cell Biology. 19:1336-1347. 2017
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 31:2529-2531. 2017
- ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. American Journal of Hematology. 92:1037-1046. 2017
-
Overall survival in lower
IPSS riskMDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: anMDS ‐CAN analysis. British Journal of Haematology. 179:83-97. 2017 - Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology. 24:833-844.e9. 2017
- A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Cell Chemical Biology. 24:493-506.e5. 2017
- Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.. American Journal of Blood Research. 7:30-40. 2017
- Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget. 7:72608-72621. 2016
- Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology. 146:408-422. 2016
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 128:934-947. 2016
-
Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an
MDS ‐CAN prospective study. British Journal of Haematology. 174:88-101. 2016 - Small molecules reveal an alternative mechanism of Bax activation. Biochemical Journal. 473:1073-1083. 2016
-
Gender and
BCR ‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. European Journal of Haematology. 96:360-366. 2016 - Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia. 15:715-727. 2015
- Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study. Atherosclerosis. 242:141-144. 2015
- Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells—Mitochondrial Outer Membrane Permeabilization and Beyond. Clinical Cancer Research. 21:2671-2676. 2015
- Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells. 33:1839-1849. 2015
- Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Biochemical Journal. 467:495-505. 2015
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 29:526-534. 2015
- Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clinical Case Reports. 3:88-91. 2015
-
Phase
II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA methyltransferase expression. British Journal of Haematology. 167:664-670. 2014 - A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults. Current Oncology. 21:234-250. 2014
- Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. Journal of Experimental Medicine (JEM). 211:1925-1935. 2014
- Regulating cell death at, on, and in membranes. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1843:2100-2113. 2014
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 124:729-736. 2014
- The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511:90-93. 2014
- Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBid. Cell Death and Disease. 5:e1277-e1277. 2014
- The Proapoptotic Protein tBid Forms Both Superficially Bound and Membrane-Inserted Oligomers. Biophysical Journal. 106:2085-2095. 2014
- Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Current Oncology. 21:265-309. 2014
- Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence. Current Oncology. 21:44-50. 2014
- Examining the Molecular Mechanism of Bcl-2 Family Proteins at Membranes by Fluorescence Spectroscopy. Methods in Enzymology. 544:1-23. 2014
- tBid Undergoes Multiple Conformational Changes at the Membrane Required for Bax Activation. Journal of Biological Chemistry. 288:22111-22127. 2013
- A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leukemia and Lymphoma. 54:760-766. 2013
- Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harbor Perspectives in Biology. 5:a008714-a008714. 2013
- Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.. American Journal of Blood Research. 3:141-164. 2013
- Shedding Light on Apoptosis at Subcellular Membranes. Cell. 151:1179-1184. 2012
- A Review of Pneumatosis Intestinalis in the Setting of Systemic Cancer Treatments, Including Tyrosine Kinase Inhibitors. Canadian Association of Radiologists Journal. 63:312-317. 2012
- GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research. 72:5374-5385. 2012
- Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. Cell Cycle. 11:3536-3542. 2012
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell. 149:1284-1297. 2012
- Multiple post-translational modifications regulate E-cadherin transport during apoptosis. Journal of Cell Science. 125:2615-2625. 2012
- Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells. Molecular Cell. 45:754-763. 2012
- Impact of temperature on cell death in a cell-culture model of hepatocellular carcinoma.. Anticancer Research. 32:915-921. 2012
- Interaction of the full-length Bax protein with biomimetic mitochondrial liposomes: A small-angle neutron scattering and fluorescence study. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1818:384-401. 2012
- Cell to cell interactions influence sensitivity of liver cell lines during hyperthermia.. Anticancer Research. 31:3713-3717. 2011
- cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure. Current Oncology. 18:185-190. 2011
- Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood. 117:7112-7120. 2011
- Effect of hyperthermia on liver cell lines: important findings for thermal therapy in hepatocellular carcinoma.. Anticancer Research. 31:1583-1588. 2011
- BH3-only proteins: Orchestrators of apoptosis. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1813:508-520. 2011
- Closing in on the link between apoptosis and autophagy. F1000 Biology Reports. 2:88. 2010
- Apoptosis: embedded in membranes. Current Opinion in Cell Biology. 22:845-851. 2010
- Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report. Journal of Pediatric Hematology/Oncology. 32:622-622. 2010
- Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene. 29:5221-5230. 2010
- The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 116:1433-1442. 2010
- Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine. 12:e28. 2010
- Proteins Required for Centrosome Clustering in Cancer Cells. Science Translational Medicine. 2:33ra38. 2010
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia and Lymphoma. 51:252-260. 2010
- BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cβ. Blood. 114:4186-4196. 2009
- A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation. 44:317-320. 2009
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114:257-260. 2009
- A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia. 23:631-634. 2009
- Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 112:4639-4645. 2008
- Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax. Cell. 135:1074-1084. 2008
- Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma. British Journal of Haematology. 143:355-360. 2008
- Iron overload in myelodysplastic syndromes: A Canadian consensus guideline. Leukemia Research. 32:1338-1353. 2008
- O-GlcNAc-glycosylation of β-catenin regulates its nuclear localization and transcriptional activity. Experimental Cell Research. 314:2774-2787. 2008
- Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax. PLoS Biology. 6:e147-e147. 2008
- Stem cell transplantation in advanced cutaneous T-cell lymphoma. Journal of American Academy of Dermatology. 58:645-649. 2008
- Acute pancreatitis preceding thrombotic thrombocytopenic Purpura. Haematologica. 92:e94-e95. 2007
- Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sanguinis. 93:173-175. 2007
- Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis : an international journal on programmed cell death. 12:897-911. 2007
- Circumvention of Fluorophore Photobleaching in Fluorescence Fluctuation Experiments: a Beam Scanning Approach. ChemPhysChem. 8:834-848. 2007
- Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer. 6:213. 2006
- Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO Journal. 25:2287-2296. 2006
- Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate. Leukemia and Lymphoma. 47:297-306. 2006
- Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO Journal. 24:2096-2103. 2005
- During Apoptosis Bcl-2 Changes Membrane Topology at Both the Endoplasmic Reticulum and Mitochondria. Molecular Cell. 14:523-529. 2004
- There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1644:115-123. 2004
- Interaction with a Membrane Surface Triggers a Reversible Conformational Change in Bax Normally Associated with Induction of Apoptosis. Journal of Biological Chemistry. 278:48935-48941. 2003
- Prolonged complete remission in two cases of acute promyelocytic leukaemia treated with atra alone. British Journal of Haematology. 117:768-768. 2002
- Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 20:205-213. 2002
- Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 20:205-213. 2002
- Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO Journal. 20:5999-6007. 2001
- Myc Potentiates Apoptosis by Stimulating Bax Activity at the Mitochondria. Molecular and Cellular Biology. 21:4725-4736. 2001
- CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene. 20:1939-1952. 2001
- Assessing pore formation by BCL-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment. Blood. 96. 2000
- The hemochromatosis gene. Clinical and Investigative Medicine. 23:334-338. 2000
- The hemochromatosis gene.. Clinical and Investigative Medicine. 23:382-386. 2000
- Mitochondrio‐nuclear translocation of AIF in apoptosis and necrosis. The FASEB Journal. 14:729-739. 2000
- Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene. 19:329-336. 2000
- Identification of the Endoplasmic Reticulum Targeting Signal in Vesicle-associated Membrane Proteins. Journal of Biological Chemistry. 274:36876-36882. 1999
- Radiotherapy to control CNS lymphomatoid granulomatosis: A case report and review of the literature. American Journal of Hematology. 62:239-241. 1999
- Regulation of Acidification and Apoptosis by SHP-1 and Bcl-2. Journal of Biological Chemistry. 274:29549-29557. 1999
- Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene. 18:3520-3528. 1999
- Inhibition of p53 Transcriptional Activity by Bcl-2 Requires Its Membrane-anchoring Domain. Journal of Biological Chemistry. 274:6469-6475. 1999
- Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene.. Clinical and Investigative Medicine. 21:251-257. 1998
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 12:1492-1493. 1998
- At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes. Oncogene. 17:565-576. 1998
- Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants. American Journal of Hematology. 56:131-142. 1997
- Evidence for Multiple Mechanisms for Membrane Binding and Integration via Carboxyl-Terminal Insertion Sequences. Biochemistry. 36:8873-8882. 1997
- Bax Homodimerization Is Not Required for Bax to Accelerate Chemotherapy-induced Cell Death. Journal of Biological Chemistry. 271:32073-32077. 1996
- Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types.. EMBO Journal. 15:4130-4141. 1996
- The role of the bone marrow in allergy and asthma. Acta Allergologica. 51:141-148. 1996
- Telomeres and Telomerase in Normal and Malignant Haematologic Cells. Leukemia and Lymphoma. 24:1-9. 1996
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 13:2386-2393. 1995
- Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85:2315-2320. 1995
- Basophil and eosinophil differentiation in allergic reactions. Journal of Allergy and Clinical Immunology. 94:1135-1141. 1994
- Targeting of passenger protein domains to multiple intracellular membranes. Biochemical Journal. 300:191-199. 1994
- Assembly of Bcl-2 into microsomal and outer mitochondrial membranes. Journal of Biological Chemistry. 269:9842-9849. 1994
- Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.. Bone Marrow Transplantation. 12:405-407. 1993
- B‐cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 85:99-102. 1993
- Nucleotide sequences of an antiidiotypic antibody from a transplant recipient. Immunogenetics. 38:242. 1993
- Rearrangement of TCR gamma chain gene involving JP1 suggests early thymocyte origin of peripheral T‐cell lymphoma. European Journal of Haematology. 42:368-374. 1989
- Abnormalities in T-cell associated rearrangement of T-cell receptor gamma chain genes in B-cell chronic lymphocytic leukemia. Leukemia Research. 13:259-266. 1989
- Characterization of Hodgkin’s Disease Derived Cell Line HDLM-2. Recent Results in Cancer Research. 117:75-82. 1989
- T-cell receptor gene rearrangement in B-Cell non-hodgkin's lymphoma: Correlation with methylation and expression. Leukemia Research. 13:473-481. 1989
- INDEPENDENT CLONAL ORIGIN OF COEXISTING CHRONIC LYMPHOCYTIC LEUKAEMIA AND MULTIPLE MYELOMA. British Journal of Haematology. 70:126-127. 1988
- Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines.. Leukemia. 2:371-376. 1988
- Mixed acute leukaemias. Blood Reviews. 2:9-15. 1988
- The nature of the hodgkin cell. Blut. 56:135-137. 1988
- Rearrangement and expression of T cell antigen receptor genes in B cell chronic lymphocytic leukemia. Blood. 71:178-185. 1988
- Patterns of gene expression during plasmacytoid differentiation of chronic lymphocytic leukaemia cells. FEBS Letters. 215:127-131. 1987
- Morphine analgesia and tolerance in the tail-flick and formalin tests: Dose-response relationships. Pharmacology Biochemistry and Behavior. 17:1213-1219. 1982